新薬NNC0638-0355が過体重または肥満を抱える人々にどのように作用するかに関する調査研究
過体重または肥満の参加者におけるNNC0638-0355の単回および複数回皮下投与の安全性、忍容性および薬物動態を評価する無作為化プラセボ対照二重盲検試験
The study is testing a new study medicine to treat people living with overweight or obesity. The aim of this study is to see if the medicine is safe, how it works in your body, and what your body does to the study medicine. Participants will either get the study medicine or placebo (a "dummy medicine" similar to the study medicine but without active ingredients) given as an injection under your skin. Which treatment the participants get is decided by chance. The study medicine is a potential new medicine which cannot be prescribed by doctors.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 1
連絡先と場所
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Key inclusion criteria
- Male or female.
- Age 18-55 years (both inclusive) at the time of signing the informed consent.
- BMI between 25.0 and 34.9 kg/m^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
- Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator.
Key exclusion criteria
-
Known or suspected hypersensitivity to study intervention(s) or related products.
-
Any condition, which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.
-
HbA1c greater than or equal to 6.5 percentage (48 mmol/mol) at screening.
-
Any laboratory safety parameters at screening outside the below laboratory ranges, see designated reference range documents for specific values:
- Vitamin D (25-hydroxycholecalciferol) less than 12 ng/mL (30 nM) at screening
- Parathyroid hormone (PTH) outside normal range at screening
- Total calcium outside normal range at screening
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:NNC0638-0355
Participants will be randomized to receive NNC0638-0355. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD) Part B, C, D and E: Multiple ascending dose (MAD). |
NNC0638-0355 will be administered as a subcutaneous (s.c. under the skin) injection. |
|
プラセボコンパレーター:Placebo
Participants will be randomized to receive Placebo. The study will be conducted in 5 parts. Part A: Single ascending dose (SAD). Part B, C,D and E: Multiple ascending dose (MAD). |
Placebo matching NNC0638-0355 will be administered as subcutaneous (s.c. under the skin) injection. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part A: Number of treatment emergent adverse events (TEAE)
時間枠:From NNC0638-0355 administration (day 1) to completion of the end of study visit (6 weeks)
|
Measured as Number of events |
From NNC0638-0355 administration (day 1) to completion of the end of study visit (6 weeks)
|
|
Part B,C,D and E : Number of treatment emergent adverse events (TEAE)
時間枠:From first NNC0638-0355 administration (day 1) to completion of the end of study visit (20 weeks)
|
Measured as Number of events |
From first NNC0638-0355 administration (day 1) to completion of the end of study visit (20 weeks)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Part A: AUC; area under the NNC0638-0355 plasma concentration-time curve
時間枠:From NNC0638-0355 administration (day 1) to completionof the end of study visit (6 weeks)
|
Measured in hours*nano mole per litre (h*nmol/L) |
From NNC0638-0355 administration (day 1) to completionof the end of study visit (6 weeks)
|
|
Part A: Cmax; maximum observed NNC0638-0355 plasma concentration
時間枠:From NNC0638-0355 administration (day 1) to completionof the end of study visit (6 weeks)
|
Measured in nano mole per litre (nmol/L) |
From NNC0638-0355 administration (day 1) to completionof the end of study visit (6 weeks)
|
|
Part B,C,D and E: AUC; area under the NNC0638-0355 plasma concentration-time curve
時間枠:From first NNC0638-0355 administration (day 1) to completionof the end of study visit (20 weeks)
|
Measured in hour*nano mole per litre (h*nmol/L) |
From first NNC0638-0355 administration (day 1) to completionof the end of study visit (20 weeks)
|
|
Part B,C,D and E: Cmax; maximum observed NNC0638-0355 plasma concentration
時間枠:From first NNC0638-0355 administration (day 1) to completionof the end of study visit (20 weeks)
|
Measured in nano mole per litre (nmol/L) |
From first NNC0638-0355 administration (day 1) to completionof the end of study visit (20 weeks)
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Transparency (dept. 2834)、Novo Nordisk A/S
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- NN9638-7569
- U1111-1296-8015 (その他の識別子:World Health Organization (WHO))
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。